OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HCSU55

HC Surgical Specialists Ltd

Healthcare Facilities & ServicesVerified

HC Surgical Specialists Ltd has a fully diluted share count of 153,375,507, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for comparison to industry benchmarks, as the valuation snapshot contains no data on return on invested capital (ROIC), operating margins, or other key performance indicators. This lack of data limits the ability to assess the company's financial health relative to its peers. The company's geographic and segment exposure is not disclosed in the available data, making it difficult to evaluate revenue concentration or diversification across business lines. Without segment or geographic breakdowns, it is unclear whether the company is exposed to specific regional or market risks. Growth trajectory is also indeterminate, as the outlook for the current and next fiscal years does not include numeric deltas or directional guidance for revenue or earnings. This absence of forward-looking data hinders the ability to project future performance. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. Dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuances. No adjustments have been applied to valuation metrics, suggesting the data is unadjusted for non-recurring items or accounting changes. Recent events, including filings or transcripts, are not disclosed in the available data, limiting insight into management commentary or strategic developments.

30-day price · HCSU+0.02 (+5.4%)
Low$0.37High$0.40Close$0.39As of16 May, 00:00 UTC
Profile
CompanyHC Surgical Specialists Ltd
TickerHCSU.SI
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. HC Surgical Specialists Ltd provides surgical services and related healthcare solutions in Singapore and the Asia-Pacific region.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

HC Surgical Specialists Ltd has a fully diluted share count of 153,375,507, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for comparison to industry benchmarks, as the valuation snapshot contains no data on return on invested capital (ROIC), operating margins, or other key performance indicators. This lack of data limits the ability to assess the company's financial health relative to its peers. The company's geographic and segment exposure is not disclosed in the available data, making it difficult to evaluate revenue concentration or diversification across business lines. Without segment or geographic breakdowns, it is unclear whether the company is exposed to specific regional or market risks. Growth trajectory is also indeterminate, as the outlook for the current and next fiscal years does not include numeric deltas or directional guidance for revenue or earnings. This absence of forward-looking data hinders the ability to project future performance. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. Dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuances. No adjustments have been applied to valuation metrics, suggesting the data is unadjusted for non-recurring items or accounting changes. Recent events, including filings or transcripts, are not disclosed in the available data, limiting insight into management commentary or strategic developments.
Key takeaways
  • The company has no dilution from stock options or convertible securities, as basic and diluted shares are equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
  • Profitability and return metrics are not available for comparison to industry benchmarks.
  • Growth trajectory and segment/geographic exposure are not disclosed in the available data.
  • No recent events or filings are available to inform strategic or operational developments.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySGD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$23.4M$10.7M$8.0M$6.5M
FY-3$19.3M$7.2M$6.4M$2.7M
FY-2$19.1M$6.3M$2.9M$746.0k
FY-1$18.8M$6.2M$3.8M$3.0M
FY0$19.1M$6.1M$8.4M$7.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$36.3M$9.8M$11.0M
FY-3$31.0M$11.0M$6.9M
FY-2$31.3M$12.1M$6.2M
FY-1$27.8M$14.7M$7.4M
FY0$27.3M$21.0M$5.1M
PeriodOCFCapExFCFSBC
FY-4$10.8M-$511.0k$6.5M
FY-3$7.1M-$220.0k$2.7M
FY-2$7.2M-$707.0k$746.0k
FY-1$6.3M-$72.0k$3.0M
FY0$7.2M-$485.0k$7.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricHCSUActivity
Op margin5.6% medp25 -4.2% · p75 12.6%
Net margin2.8% medp25 -3.4% · p75 8.8%
Gross margin36.5% medp25 23.7% · p75 65.2%
CapEx / revenue-4.9% medp25 -11.5% · p75 -2.0%
Debt / equity69.3% medp25 7.9% · p75 120.9%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:31 UTC#12503f78
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:45 UTCJob: ccefba81